Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease
Authors not listed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2004
Abstract
The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2004). Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease. <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00082602
Vancouver
Anonymous. Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2004.
BibTeX
@misc{anon2004Galant,
title = {Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease},
author = {Anonymous},
journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.},
year = {2004},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 1997
Open access · US-GOV
Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial
Janssen Research & Development, LLC 2013
Open access · US-GOV
A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects
Chong Kun Dang Pharmaceutical 2019
Open access · US-GOV
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
Kyowa Kirin Co., Ltd. 2017
Open access · US-GOV
A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2001
Open access · US-GOV
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
Vigil Neuroscience, Inc. 2023
Open access · US-GOV